The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies
- PMID: 32808135
- DOI: 10.1007/s11605-020-04771-8
The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies
Abstract
Background: Peritoneal carcinomatosis, from a variety of gastrointestinal and gynecological malignancies, has been historically challenging to treat and there remains a wide range of biologic aggressiveness in these patients. Malignancies commonly associated with PC include those of colorectal, appendiceal, gastric, ovarian, sarcoma, small intestinal, and primary peritoneal origin among others. Advances in our understanding of this unique disease process have led to significant interest in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) as an emerging treatment option. The goal of CRS-HIPEC is to remove all visible macroscopic disease while preserving organ function, and then treat microscopic disease through perfusion of the peritoneal cavity with heated chemotherapy.
Purpose: Although recent reviews have focused on the management of peritoneal carcinomatosis secondary to colorectal cancer given the publication of several recent randomized controlled trials, the purpose of the current review is to summarize the evidence on CRS-HIPEC for non-colorectal peritoneal surface malignancies, including appendiceal neoplasms, malignant peritoneal mesothelioma, gastric cancer, and ovarian cancer.
Results: While retrospective studies have clarified the importance of prognostic factors such as the peritoneal carcinomatosis index, completeness of cytoreduction, histopathological characteristics, and lymph node positivity, the lack of convincing level 1 evidence for the use of CRS-HIPEC has led to it remaining a highly controversial topic.
Conclusion: The decision to utilize CRS-HIPEC should involve a multidisciplinary team approach and evaluation of prognostic factors to balance the short-term morbidity of the operation with maximum long-term benefits. Large, multi-institutional groups and ongoing trials hold promise for clarifying the role of CRS-HIPEC in peritoneal surface malignancies.
Keywords: Appendiceal cancer; Cytoreductive surgery; Gastric cancer; HIPEC; Hyperthermia; Mesothelioma; Ovarian cancer.
Similar articles
-
[Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Mar 25;24(3):230-239. doi: 10.3760/cma.j.cn.441530-20201110-00603. Zhonghua Wei Chang Wai Ke Za Zhi. 2021. PMID: 34645167 Chinese.
-
The robotic future of minimally invasive cytoreduction and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.Chin Clin Oncol. 2023 Apr;12(2):16. doi: 10.21037/cco-22-118. Epub 2023 Mar 13. Chin Clin Oncol. 2023. PMID: 36946185 Review.
-
Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Ann Surg Oncol. 2015 May;22(5):1716-21. doi: 10.1245/s10434-014-3985-y. Epub 2014 Aug 22. Ann Surg Oncol. 2015. PMID: 25145504 Clinical Trial.
-
Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.Surg Oncol. 2022 Aug;43:101766. doi: 10.1016/j.suronc.2022.101766. Epub 2022 Apr 8. Surg Oncol. 2022. PMID: 35430126
-
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.Eur J Cancer. 2020 Mar;127:76-95. doi: 10.1016/j.ejca.2019.10.034. Epub 2020 Jan 24. Eur J Cancer. 2020. PMID: 31986452
Cited by
-
Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes.Cancers (Basel). 2022 Dec 6;14(23):6010. doi: 10.3390/cancers14236010. Cancers (Basel). 2022. PMID: 36497490 Free PMC article. Review.
-
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of non-primary origin.Langenbecks Arch Surg. 2021 Dec;406(8):2817-2825. doi: 10.1007/s00423-021-02354-y. Epub 2021 Oct 23. Langenbecks Arch Surg. 2021. PMID: 34686891
References
-
- Sugarbaker, PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res 1996;82(79-100. - PubMed
-
- Jacquet, P and Sugarbaker, PH. Peritoneal-plasma barrier. Cancer Treat Res 1996;82(53-63.
-
- Spratt, JS, Adcock, RA, Sherrill, W, and Travathen, S. Hyperthermic peritoneal perfusion system in canines. Cancer Res 1980;40(2):253-255. - PubMed
-
- Sugarbaker, PH. Peritoneal carcinomatosis: natural history and rational therapeutic interventions using intraperitoneal chemotherapy. Cancer Treat Res 1996;81(149-168. - PubMed
-
- Sugarbaker, PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia 2007;23(5):431-442. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical